US20030119913A1 - Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof - Google Patents

Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof Download PDF

Info

Publication number
US20030119913A1
US20030119913A1 US10/115,266 US11526602A US2003119913A1 US 20030119913 A1 US20030119913 A1 US 20030119913A1 US 11526602 A US11526602 A US 11526602A US 2003119913 A1 US2003119913 A1 US 2003119913A1
Authority
US
United States
Prior art keywords
composition
person
administering
comprises administering
serotonin levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/115,266
Other languages
English (en)
Inventor
Sunny Ohia
Harry Preuss
Debasis Bagchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Consumer Health Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23346261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030119913(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/115,266 priority Critical patent/US20030119913A1/en
Assigned to INTERHEALTH NUTRACEUTICALS INCORPORATED reassignment INTERHEALTH NUTRACEUTICALS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PREUSS, HARRY G., OHIA, SUNNY E., BAGCHI, DEBASIS
Publication of US20030119913A1 publication Critical patent/US20030119913A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates generally to a method for increasing serotonin levels in a person.
  • the present invention also relates to compositions that, when administered to a person, increase serotonin levels in the person.
  • Serotonin (or 5-hydroxytryptamine, 5HT) is a neurotransmitter believed to be involved a wide range of mental and physical functions in the body, including sleep, mood, and eating behavior. Serotonin deficiency has been implicated in a variety of conditions, including depression, low energy, anxiety, affective disorder, obsessive-compulsive behavior, overeating, insomnia, schizophrenia, migraine headaches and bulimia. It is well established that serotonin and peptides such as neuropeptide Y are involved in the regulation of eating behavior. Increased brain levels of serotonin have been linked with appetite suppression in preclinical experiments in animals and in clinical studies with human patients. These conditions can be resolved or improved dramatically when serotonin levels of the affected person are increased.
  • serotonin selective re-uptake inhibitors e.g., fluoxetine
  • compounds promoting production of serotonin e.g., St. John's Wort
  • compounds inhibiting the degradation of serotonin e.g., monoamine oxidase inhibitor antidepressants.
  • monoamine oxidase inhibitor antidepressants e.g., monoamine oxidase inhibitor antidepressants
  • FIG. 1 is a graphical representation of the effect of exposure to ( ⁇ )-hydroxycitric acid (HCA) on the release of radiolabeled serotonin from isolated, superfused, rat brain cortex slices. Stimuli were applied as follows: potassium chloride (K+, 50 mM) standard response at fractions 5 and 6 (S 1 ) and HCA at fractions 13 and 14 (S 2 ). Fractions of the superfusate were collected at 6-minute intervals and analyzed for radioactivity as described herein.
  • K+, 50 mM potassium chloride
  • S 1 fractions 5 and 6
  • S 2 Fractions of the superfusate were collected at 6-minute intervals and analyzed for radioactivity as described herein.
  • FIG. 2 is a graphical representation of the effect of exposure to ( ⁇ )-hydroxycitric acid (HCA) on radiolabeled serotonin release from isolated, superfused rat brain cortex: control (K+) and in the presence of HCA (10 ⁇ M -1 mM). Vertical bars represent means ⁇ S.E.M. The number of observations is in parenthesis.
  • HCA ⁇ -hydroxycitric acid
  • FIG. 3 is a graphical representation of the increase in serum serotonin level, increase in loss of body weight, and increase in unconsumed food observed in persons treated using methods of the present invention: control (placebo), ( ⁇ )-hydroxycitric acid (HCA), and HCA plus chromium and gymnemic acid (HCA+).
  • the present invention resides in a method for increasing serotonin levels in a person, comprising identifying a person having or at risk for having a deficient serum serotonin levels, and administering to the person a composition incorporating an amount of ( ⁇ )-hydroxycitric acid effective to increase the serotonin levels of the person.
  • the amount of ( ⁇ )-hydroxycitric acid administered is effective in increasing the serotonin levels in the person sufficient to suppress the appetite of or alleviate mood disorders in the person.
  • mood disorders preferably alleviated include depression, anxiety, affective disorders, premenstrual dysphoria, insomnia, sleep-wake disturbances, binge eating, bulemia and obsessive-compulsive disorders.
  • the amount of ( ⁇ )-hydroxycitric acid administered also may preferably be effective to increase serotonin levels in the person sufficient to increase energy expenditure by the person, or to promote decrease of the person's body weight.
  • the method preferably incorporates administration of an extract of Garcinia cambogia as a source of the ( ⁇ )-hydroxycitric acid.
  • the amount administered preferably is between about 2,700 and about 2,800 mg of ( ⁇ )-hydroxycitric acid per day, in three approximately equal increments, preferably between about 45 and 60 minutes prior to comsumption of a meal.
  • Preferred methods also incorporate administering an amount of chromium sufficient, in combination with the ( ⁇ )-hydroxycitric acid, to increase serum serotonin level in the person, in a preferred daily dose of 400 mcg.
  • This chromium preferably is in the form of an niacin-bound, and more preferably oxygen-coordinated, niacin-bound, chromium.
  • Preferred methods also incorporate administering an amount gymnemic acid sufficient, in combination with the ( ⁇ )-hydroxycitric acid, to increase serum serotonin level, in a preferred daily dose of 100 mg.
  • the preferred source of gymnemic acid is an extract of Gymnema sylvestre.
  • the present invention also resides in a composition incorporating hydroxycitric acid, niacin-bound chromium, and gymnemic acid, in the preferred individual dosages discussed above (i.e., between about 900 and 930 mg ( ⁇ )-hydroxycitric acid, about 133 mcg chromium, and about 33 mg gymnemic acid).
  • compositions consist essentially of an extract of Garcinia cambogia, an extract of Gymnema sylvestre, and niacin-bound chromium, preferably in amounts to provide the amounts of hydroxycitric acid, niacin-bound chromium, and gymnemic acid discussed above (i.e., between about 1,500 and 1,550 mg of Garcinia cambogia, about 1.3 mg of niacin-bound chromium, and about 130 mg of extract of Gymnema sylvestre ).
  • the composition may be in the form of a pill, tablet, capsule, powder, lozenge, or gum, or liquid.
  • the composition also may be in the form of a food or beverage, such as a food bar or shake.
  • the present invention resides in a method for increasing serotoninx levels in persons and alleviating various conditions linked to serotonin deficiency in those persons.
  • the method includes identifying a person who is or is at risk for having deficient serotonin levels and administering to the person a composition comprising a salt of ( ⁇ )-hydroxycitric acid (HCA) in an amount effective to alleviate the deficiency.
  • HCA ⁇ -hydroxycitric acid
  • the present invention also resides in a composition comprising HCA, chromium, and gymnemic acid, preferably as a composition consisting essentially of preferred sources of HCA, chromium, and gymnemic acid.
  • HCA Ingestion of a salt of ( ⁇ )-hydroxycitric acid is known to suppress appetite, inhibit fat production and decreases body weight in animals and persons. HCA has been shown to reduce food intake in experimental animals, suggesting a role for this agent in the treatment of obesity. HCA is a competitive inhibitor of ATP-citrate lyase, an extra-mitochondrial enzyme involved in the initial steps of de novo lipogenesis. Consequently, HCA reduces the transformation of citrate into acetyl coenzyme A, a step necessary for the formation of fatty acids in the liver. In the presence of HCA, there is increased production of hepatic glucogen, which has been believed to activate glucoreceptors leading to a sensation of fullness and reduced appetite. This mechanism of appetite suppression, however, has never been proven. It also has been shown that HCA-induced increases in energy expenditure may account, at least in part, for the observed inhibitory effect of this anorectic agent on body weight gain in rats.
  • a preferred known composition incorporating HCA for use in the methods of the present invention is an extract of the Garcinia cambogia fruit containing approximately 60% calcium/potassium salt of ( ⁇ )-hydroxycitric acid, marketed under the name Super CitriMaxTM by InterHealth Nutraceuticals of Benicia, Calif.
  • This extract is highly soluble in water, and it is readily absorbed and retained by persons. Studies have shown that blood levels of the extract increase for at least 2 hours and remained in the blood for more than 4 to 9 hours after ingestion. Studies also show that eating a full meal shortly after consuming the extract reduced its absorption by about 60%. Thus, it is recommended that compositions containing the extract be taken at least 30 to 60 minutes before meals to provide maximum efficacy.
  • Preferred aspects of the method of the present invention incorporate administering compositions comprising chromium, gymnemic acid, or both of these. It has been surprisingly determined that consumption by persons of HCA in combination with these compounds provides for even greater increases in serotonin levels than consumption of HCA alone.
  • Chromium incorporated into the compositions used in the method of the present invention preferably is in an oxygen-coordinated, niacin-bound form.
  • This form of chromium is known to be more bioavailable and biologically active that other known forms.
  • a preferred source of this chromium is described in U.S. Pat. Nos. 4,934,855, 4,954,492, and 5,194,615 and is supplied by InterHealth Nutraceuticals, marketed under the name ChromeMate®. ChromeMate® has been shown to promote weight loss and loss of body fat in persons ingesting it, with no adverse effects observed from this ingestion. No prior studies on chromium, however, have determined or suggested increases in serotonin levels from ingestion of chromium, either alone or in combination with other compounds.
  • Gymnemic acid has been shown to increase the production of insulin by stimulating the production of new insulin-promoting “beta-cells” cells in the pancreas. Gymnemic acid also facilitates insulin release from the beta-cells into the blood stream by increasing beta-cell membrane permeability, and inhibits the absorption of sugar molecules in the intestines during digestion, thus reducing increases in blood sugar levels.
  • a preferred source of gynnemic acid in compositions used with the method of the present invention is Gymnema sylvestre extract supplied by InterHealth Nutraceuticals of Benicia, Calif. Gymnema sylvestre is a traditional Ayurvedic herb that is known to play a role in weight control by helping to promote normal blood sugar levels and reduce sugar cravings. Gymnema sylvestre also has also been shown to lower cholesterol in animal models. Despite its known properties, gymnemic acid or the Gymnema sylvestre previously have not been determined to affect serotonin levels in persons ingesting them.
  • Particularly referred methods of the present invention include administration of a composition incorporating between approximately 2,700 and 2,800 mg of HCA daily. Preferred administration of the composition is orally, in three daily doses roughly 30 to 60 minutes before meals. Additional preferred methods include administration of a composition further incorporating approximately 100 mg of gymnemic acid, or approximately 400 mcg of chromium, or both of these.
  • the preferred source of gymnemic acid is Gymnema sylvestre extract. Approximately 400 mg of Gymnema sylvestre extract serves as a source of 100 mg of gymnemic acid.
  • the preferred source of chromium is ChromeMateTM, the oxygen-coordinated, niacin-bound chromium previously discussed. Approximately 4 mg of ChromeMateTM serves as a source of 400 mcg of chromium.
  • Methods of the present invention also include administration of compositions incorporating inert ingredients or diluents, such as sugar or other inert ingredients commonly used in food products.
  • the composition administered may be in various forms commonly used for dietary supplements, including pill, tablet, capsule, powder, lozenge, gum, or liquid.
  • the step of administering can include administering the compositions as part of functional foods and beverages, including bars, shakes, drinks, and other processed or prepared foods or beverages.
  • the Krebs solution used had the following composition (millimolar): potassium chloride, 4.8; sodium chloride 118; calcium chloride, 1.3; potassium dihydrogen phosphate, 1.2; sodium bicarbonate, 25; magnesium sulfate, 2.0; and dextrose, 10 (pH 7.4).
  • Both K+ and HCA-induced radiolabeled serotonin release were estimated by subtraction of the extrapolated basal tritium efflux from total tritium release in the 20-minute period after the onset of stimulation. Basal (unstimulated) tritium efflux was assumed to decline linearly between pre-stimulation and post-stimulation fractions. Stimulation-evoked radiolabeled serotonin release during S 1 and S 2 was determined graphically, and the ratio of the two peaks (S 1 /S 2 ) was calculated and compared with untreated control preparations.
  • Results obtained were expressed as absolute S 1 /S 2 ratios. Data from different experiments (control and test) were pooled and then subjected to statistical analysis. Except where indicated otherwise, values given are arithmetic means ⁇ SEM. Significance of difference between control and test values was evaluated using analysis of variance (ANOVA) followed by Dunnett's test. Differences with P values ⁇ 0.05 were accepted as statistically significant.
  • Results of the experiment are illustrated in FIGS. 1 and 2.
  • Application of an iso-osmotic concentration of K+ (50 mM) elicited a peak of overflow of radiolabeled serotonin release, an effect that can be repeated more than twice in the same slice of brain cortex.
  • the effect of different concentrations of HCA (10 ⁇ M-1 mM) applied 12 minutes before the second K+ stimuli (S 2 ) were examined.
  • HCA had no significant effect on the second K+ response even though it changed the baseline of spontaneous radiolabeled serotonin efflux. Consequently, the direct effect of HCA on basal radiolabeled serotonin release from brain cortex slices were investigated. For these experiments, the K+ stimulus was applied at S 1 , and then the effect of HCA on basal tritium efflux was tested at fraction number 12. As represented by the illustration in FIG. 1, HCA (300 ⁇ M) elicited an increase in the release of radiolabeled serotonin over baseline values. Next, the effect of different concentrations of HCA (10 ⁇ M-1 mM) on basal release of radiolabeled serotonin from cortical slices was examined.
  • HCA caused a concentration-related increase in basal efflux of radiolabeled serotonin, reaching a maximum at 300 ⁇ M (FIG. 2).
  • the overflow of radiolabeled serotonin induced by the maximal concentration of HCA (300 ⁇ M) was equivalent to the release induced by the standard concentration of K+ (50 mM).
  • HCA alters the release and/or availability of serotonin in the brain slices, specifically by increasing the release of serotonin from neuronal stores in the brain cortex in a concentration-dependent fashion. Exposure of the rat brain cortex slices to different concentrations of HCA had no significant effect on K+-depolarization evoked release of radiolabeled serotonin. However, on its own, HCA increased the basal release of tritium-labeled 5-HT in a concentration-dependent fashion. The maximal effect caused by HCA on radiolabeled serotonin release was equivalent to responses elicited by the K+ depolarizing stimuli.
  • HCA may act via a “reserpine-like” or “tyramine-like” action to increase the efflux of radiolabeled pools of 5-HT in the brain cortex.
  • a reserpine-like action may involve HCA induced interference with the storage of radiolabeled serotonin in vesicles whereas, a tyramine-like effect could involve vesicular release of radiolabeled serotonin in a non-exocytoxic manner.
  • HCA may act to prevent the reuptake of released radiolabeled serotonin, resulting in an increased efflux of this amine into the superfusate.
  • compositions within the scope of the present invention were tested.
  • a double-blind, placebo-controlled human clinical trial was conducted using a composition incorporating: the HCA extract described above, or the HCA extract in combination with an oxygen-coordinated niacin-bound chromium (ChromeMate®, supplied by InterHealth), and a standardized Gymnema sylvestre extract (also supplied by InterHealth).
  • ChromeMate® oxygen-coordinated niacin-bound chromium
  • Gymnema sylvestre extract also supplied by InterHealth
  • the subjects were randomly divided into three groups. The first group was given a placebo. The second group was given a daily dose of 4,667 mg of garcinia cambogia extract (providing 2,800 mg HCA per day). The third group was given a daily dose of 4,667 mg of a combination of garcinia cambogia (2,800 mg HCA), 4 mg of niacin-bound chromium (providing 400 mcg of elemental chromium), and 400 mg of Gymnema sylvestre extract (providing 100 mg gymnemic acid). The subjects received their respective compositions in three equally-divided doses 30 to 60 minutes before breakfast, lunch and dinner for eight weeks. These dosage levels of HCA were determined by extrapolation of successful earlier animal trials, as well as review of optimal micromolar concentrations of HCA in ex vivo brain tissue resulting in maximum serotonin release.
  • the persons were assessed for changes in serum serotonin levels, body weight, and food intake. As discussed above, increases in serum serotonin levels relate to reduced appetite. Food intake was measured by monitoring the amount of food left unconsumed after each meal by the subjects. The amount of food left unconsumed while taking either the placebo or either of the HCA compositions was compared to the amount of food left unconsumed before the subjects began taking the compositions (i.e., the baseline). Changes in each of these factors were measured in the persons and averaged to produce the figures in Table 1.
  • Results of the testing are shown in Table 1 below and FIG. 3. TABLE 1 Results of Administration of Compositions HCA + chromium + Tested Factor Placebo HCA gymnemic acid Body weight Pounds lost 3.5 10.0 12.8 % decrease 1.9 5.0 6.5 Serum serotonin level mg/dl increase 20.1 119.1 149.3 % increase 10.9 48.5 70.4 Food left unconsumed grams 71.9 249 328 % increase from (3.6) 206 370 baseline
  • combining consumption of HCA with oxygen-coordinated niacin-bound chromium (incorporating elemental chromium), and Gymnema sylvestre extract (incorporating gymnemic acid), provides for increased efficacy of the method, increasing serum serotonin levels greater than consumption of HCA alone, further improving alleviation of the negative conditions discussed above.
  • Administration of the three compounds works synergistically to substantially increase serotonin levels in persons consuming the compounds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
US10/115,266 2001-12-20 2002-04-02 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof Abandoned US20030119913A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/115,266 US20030119913A1 (en) 2001-12-20 2002-04-02 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34347301P 2001-12-20 2001-12-20
US10/115,266 US20030119913A1 (en) 2001-12-20 2002-04-02 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof

Publications (1)

Publication Number Publication Date
US20030119913A1 true US20030119913A1 (en) 2003-06-26

Family

ID=23346261

Family Applications (8)

Application Number Title Priority Date Filing Date
US10/115,266 Abandoned US20030119913A1 (en) 2001-12-20 2002-04-02 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
US10/325,675 Abandoned US20040014692A1 (en) 2001-12-20 2002-12-20 Compositions incorporating(-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,181 Abandoned US20050008726A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,096 Abandoned US20050008723A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,791 Abandoned US20050013887A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,180 Abandoned US20050008725A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,173 Abandoned US20050008724A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,095 Expired - Lifetime US7335651B2 (en) 2001-12-20 2004-08-03 Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation

Family Applications After (7)

Application Number Title Priority Date Filing Date
US10/325,675 Abandoned US20040014692A1 (en) 2001-12-20 2002-12-20 Compositions incorporating(-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,181 Abandoned US20050008726A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,096 Abandoned US20050008723A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,791 Abandoned US20050013887A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,180 Abandoned US20050008725A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,173 Abandoned US20050008724A1 (en) 2001-12-20 2004-08-03 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US10/911,095 Expired - Lifetime US7335651B2 (en) 2001-12-20 2004-08-03 Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation

Country Status (10)

Country Link
US (8) US20030119913A1 (enExample)
EP (1) EP1461051A1 (enExample)
JP (1) JP2005513107A (enExample)
AU (1) AU2002364213B2 (enExample)
CA (1) CA2463427A1 (enExample)
IL (1) IL161212A0 (enExample)
MX (1) MXPA04006166A (enExample)
NZ (1) NZ532550A (enExample)
WO (1) WO2003053454A1 (enExample)
ZA (1) ZA200402687B (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063940A1 (en) * 1998-12-29 2004-04-01 Pfizer Inc 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives
US20050009919A1 (en) * 2003-07-07 2005-01-13 Clouatre Dallas L. Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
US20050032901A1 (en) * 2002-07-02 2005-02-10 Clouatre Dallas L. (-)-Hydroxycitric acid for controlling inflammation
US20050215644A1 (en) * 2004-03-19 2005-09-29 Interhealth Nutraceuticals, Inc. Methods for increasing neurotransmitter levels using hydroxycitric acid
US20050232952A1 (en) * 2002-03-01 2005-10-20 Gregory Lambert Self emulsifying drug delivery systems for poorly soluble drugs
US20050249827A1 (en) * 2004-04-30 2005-11-10 Gardiner Paul T Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite
US20060025483A1 (en) * 2004-07-29 2006-02-02 Clouatre Dallas L (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification
US7153877B2 (en) 2001-10-05 2006-12-26 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US7335651B2 (en) 2001-12-20 2008-02-26 Interhealth Nutraceuticals Incorporated Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation
US7858128B2 (en) 1997-07-14 2010-12-28 Interhealth Nutraceuticals, Inc. Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
WO2018057737A1 (en) * 2016-09-22 2018-03-29 Cash Alan B Method to alleviate the symptoms of pms

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157929A1 (en) * 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
JP2004181452A (ja) * 2002-11-30 2004-07-02 Matsushita Electric Ind Co Ltd 洗浄装置、洗浄方法および洗浄剤
TW200427447A (en) * 2003-03-21 2004-12-16 Interhealth Nutraceuticals Inc Method and composition for decreasing ghrelin levels
US20050053555A1 (en) * 2003-07-14 2005-03-10 Crave Busters, Llc. Appetite control compositions and methods of use
US20050256192A1 (en) 2004-04-30 2005-11-17 Gardiner Paul T Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, increasing nutrient delivery and/or promoting increased vascular response in an individual
WO2006033476A1 (en) * 2004-09-24 2006-03-30 Showa Denko K.K. Hydroxycitric acid derivatives and skin external preparations containing the same
CN101141888A (zh) * 2004-12-14 2008-03-12 聪明燃烧制剂有限公司 促进减肥的辅助性膳食组合物
US7912716B2 (en) * 2005-10-06 2011-03-22 Sony Online Entertainment Llc Generating words and names using N-grams of phonemes
WO2008048574A2 (en) * 2006-10-18 2008-04-24 Dallas Clouatre Hca for improved hdl serum lipids profile
US20100323031A1 (en) * 2009-06-22 2010-12-23 Glykon Technologies Group, Llc Synergistic combination to enhance blood glucose and insulin metabolism
US20100323043A1 (en) * 2009-06-23 2010-12-23 Perla Marc D Antimicrobial Compositions and Methods of Making and Using the Same
US9931365B2 (en) 2010-09-28 2018-04-03 Lisa Geng Methods for treating neurological disorders using nutrient compositions
WO2012050895A1 (en) 2010-09-28 2012-04-19 Lisa Geng Methods for treating neurological disorders using nutrient compositions
WO2013036715A1 (en) * 2011-09-07 2013-03-14 Massoud Arvanaghi Capsaicin composition and method related thereto
CN110882390B (zh) * 2019-11-15 2022-03-15 西安交通大学医学院第一附属医院 人lsm5基因的用途及相关产品
EP4156970A4 (en) 2020-06-02 2024-06-19 Glykon Technologies Group, LLC. Reducing triglyceride levels and cortisol levels with pharmaceutical preparations

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US133992A (en) * 1872-12-17 Improvement in bed-lounges
US14692A (en) * 1856-04-15 Improved diaphragm fluid-meter
US220329A (en) * 1879-10-07 Improvement in pounder washing-machines
US132219A (en) * 1872-10-15 Improvement in combined knife-sharpeners and glass-cutters
US44469A (en) * 1864-09-27 Improved clothes-drier
US3764692A (en) * 1970-09-30 1973-10-09 Hoffmann La Roche Method of treating obesity
US4923855A (en) 1983-07-08 1990-05-08 The William Seroy Group Synthetic GTF chromium material and process therefor
US5194615A (en) * 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
US4954492A (en) * 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
JPS62236469A (ja) * 1986-04-04 1987-10-16 Yasutake Hichi 低カロリ−飲食物
US5266560A (en) * 1988-06-03 1993-11-30 Thomas Research Corporation Pharmaceutical insulin-potentiating CR(III) complexes with GTF-like activity
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5480657A (en) * 1993-10-27 1996-01-02 Allen; Ann De Wees T. Composition comprising caffeine chromium and fructose for weight control and use thereof
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
US5567424A (en) * 1994-06-10 1996-10-22 Reliv International, Inc. Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption
US6352713B1 (en) * 1999-12-01 2002-03-05 Drugtech Corporation Nutritional composition
US5536516A (en) * 1994-08-24 1996-07-16 Renaissance Herbs, Inc. Hydroxycitric acid concentrate and food products prepared therefrom
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AU5736096A (en) * 1995-05-15 1996-11-29 Sabinsa Corporation A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy cit ric acid
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
IT1276253B1 (it) * 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
US5716976A (en) * 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
FI120290B (fi) 1996-12-30 2009-09-15 Mirador Res Oy Ltd Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
JP3736776B2 (ja) 1997-03-25 2006-01-18 宝ホールディングス株式会社 新規カルシウム組成物
US5981510A (en) * 1997-04-15 1999-11-09 Yaizu Suisankagaku Industry Co., Ltd. Method for treating and improving diabetes
US5911992A (en) * 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia
EP1011660A1 (en) 1997-07-14 2000-06-28 Inter-Health Nutraceuticals Incorporated Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US5877171A (en) * 1997-07-28 1999-03-02 Mcleod; Malcolm N. Method of treating pre-menstrual syndrome using chromium
US6160172A (en) * 1997-08-27 2000-12-12 Vittal Mallya Scientific Research Foundation Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties
KR100704523B1 (ko) * 1998-02-23 2007-04-09 다이요 가가꾸 가부시끼가이샤 테아닌 함유 조성물
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
AU5142699A (en) * 1998-07-31 2000-02-28 Mount Sinai Hospital Corporation Methods and compositions for increasing insulin sensitivity
US5905075A (en) * 1998-08-28 1999-05-18 Ambi Inc. Chromium nicotinate compositions and uses thereof
WO2000012080A1 (en) * 1998-09-01 2000-03-09 Amway Corporation Diet composition and method of weight management
US6252713B1 (en) * 1998-10-28 2001-06-26 Asahi Kogaku Kogyo Kabushiki Kaisha Optical device provided with correcting function for trembling of focused image
WO2000048983A1 (en) 1999-02-18 2000-08-24 Vittal Mallya Scientific Research Foundation Soluble double metal salt of group ia and iia of (-) hydroxycitric acid
AU4326500A (en) 1999-03-26 2000-10-16 Akesis Pharmaceuticals, Inc. Beverages for treatment of glucose metabolism disorders
US6447807B1 (en) 1999-09-14 2002-09-10 Dallas L. Clouatre Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
US6207714B1 (en) * 1999-09-14 2001-03-27 Dallas L. Clouatre Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
US20030220329A1 (en) * 1999-09-17 2003-11-27 Duke University Method of improving beta-adrenergic receptor function
US6541026B2 (en) * 1999-12-16 2003-04-01 Harry J. Siskind Nutritional composition, methods of producing said composition and methods of using said composition
US6291533B1 (en) * 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
US7015250B2 (en) * 2000-02-09 2006-03-21 Glykon Technologies Group, Llc Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid
US6399089B1 (en) * 2000-05-15 2002-06-04 A. Glenn Braswell Compositions and methods for regulating metabolism and balancing body weight
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
DE60104450T2 (de) * 2000-09-21 2005-09-15 Nutrition 21, Inc. Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils
US6579866B2 (en) * 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US6420350B1 (en) * 2001-01-18 2002-07-16 Goen Group, Inc. Weight loss product
US20020133992A1 (en) * 2001-03-20 2002-09-26 Julie Wu Magnetic display device
AU2002305132B2 (en) * 2001-03-30 2007-05-31 Lonza Consumer Health Inc. Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
US20040157929A1 (en) * 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
US6476071B1 (en) 2001-05-07 2002-11-05 Dallas L. Clouatre Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid
US6441041B1 (en) * 2001-06-20 2002-08-27 Dallas L. Clouatre (-)-hydroxycitric acid for the prevention of osteoporosis
US6482858B1 (en) * 2001-06-20 2002-11-19 Dallas L Clouatre (−)-hydroxycitric acid for wound healing and immunomodulation
US6638542B2 (en) * 2001-09-20 2003-10-28 Nutricia N.V. Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US20030119913A1 (en) * 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
AU2003225196A1 (en) 2002-04-30 2003-11-17 Unibar Corporation Hydroxycitric acid salt composition and method of making
US6967030B2 (en) * 2003-01-14 2005-11-22 Wright Jonathan V Formulation for insulin and glucose control
TW200427447A (en) * 2003-03-21 2004-12-16 Interhealth Nutraceuticals Inc Method and composition for decreasing ghrelin levels

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943186B2 (en) 1997-07-14 2011-05-17 Interhealth Nutraceuticals, Inc. Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US7927636B1 (en) 1997-07-14 2011-04-19 Interhealth Nutraceuticals, Inc. Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US7858128B2 (en) 1997-07-14 2010-12-28 Interhealth Nutraceuticals, Inc. Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US20040063940A1 (en) * 1998-12-29 2004-04-01 Pfizer Inc 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives
US7153877B2 (en) 2001-10-05 2006-12-26 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US7335651B2 (en) 2001-12-20 2008-02-26 Interhealth Nutraceuticals Incorporated Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation
US20050232952A1 (en) * 2002-03-01 2005-10-20 Gregory Lambert Self emulsifying drug delivery systems for poorly soluble drugs
US20050032901A1 (en) * 2002-07-02 2005-02-10 Clouatre Dallas L. (-)-Hydroxycitric acid for controlling inflammation
US8394856B2 (en) 2002-07-02 2013-03-12 Glykon Technologies Group, Llc (-)-Hydroxycitric acid for controlling inflammation
US20050009919A1 (en) * 2003-07-07 2005-01-13 Clouatre Dallas L. Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
US20050215644A1 (en) * 2004-03-19 2005-09-29 Interhealth Nutraceuticals, Inc. Methods for increasing neurotransmitter levels using hydroxycitric acid
US20050249827A1 (en) * 2004-04-30 2005-11-10 Gardiner Paul T Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite
US20060025483A1 (en) * 2004-07-29 2006-02-02 Clouatre Dallas L (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification
WO2018057737A1 (en) * 2016-09-22 2018-03-29 Cash Alan B Method to alleviate the symptoms of pms
JP2019529559A (ja) * 2016-09-22 2019-10-17 アラン ビー． キャッシュ， Ｐｍｓの症状を軽減する方法
US11071722B2 (en) 2016-09-22 2021-07-27 Alan B. Cash Method to alleviate the symptoms of PMS
JP7291079B2 (ja) 2016-09-22 2023-06-14 アラン ビー． キャッシュ， Ｐｍｓの症状を軽減する方法
US11865092B2 (en) 2016-09-22 2024-01-09 Alan B. Cash Method to alleviate the symptoms of PMS
US12324794B2 (en) 2016-09-22 2025-06-10 Alan B. Cash Method to alleviate the symptoms of PMS

Also Published As

Publication number Publication date
JP2005513107A (ja) 2005-05-12
MXPA04006166A (es) 2005-07-05
CA2463427A1 (en) 2003-07-03
US20050008726A1 (en) 2005-01-13
NZ532550A (en) 2005-09-30
ZA200402687B (en) 2005-02-23
AU2002364213B2 (en) 2007-03-15
US20050008724A1 (en) 2005-01-13
US20040014692A1 (en) 2004-01-22
US20050013887A1 (en) 2005-01-20
WO2003053454A1 (en) 2003-07-03
US20050008725A1 (en) 2005-01-13
AU2002364213A1 (en) 2003-07-09
US20050008723A1 (en) 2005-01-13
EP1461051A1 (en) 2004-09-29
US7335651B2 (en) 2008-02-26
US20050008722A1 (en) 2005-01-13
IL161212A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
US20030119913A1 (en) Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
US20080139657A1 (en) Method for increasing serotonin levels in a person by administration of a composition incorporating (-)hydroxycitric acid, and related compositions thereof
WO2005107779A2 (en) Weight loss composition and method of inducing weight loss
AU2002305132B2 (en) Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
AU2002305132A1 (en) Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
US7338672B2 (en) Herbal supplement for cognitive related impairment due to estrogen loss
KR101596728B1 (ko) 아연/홍삼, 옥타코사놀 및 비타민을 포함하는, 남성 갱년기 증상의 예방 및 개선용 조성물
US6887499B2 (en) Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
US20030039708A1 (en) Non-ma huang herb weight loss product
RU2146529C1 (ru) Набор антиалкогольных средств
US6465021B2 (en) Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
EP1261345B1 (en) Herbal supplement for cognitive related impairment due to estrogen loss
TW200841827A (en) A nutritional supplement for adjustment of blood pressure and protection of cardio-vascular and cerebro-vascular systems
Badmaev et al. Coleus forskohlii: Fat-Fighting and More
WO2008152624A2 (en) Herbal energy-enhancing formulation
AU2007202775A1 (en) Compositions incorporating (-)- hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTERHEALTH NUTRACEUTICALS INCORPORATED, CALIFORNI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OHIA, SUNNY E.;PREUSS, HARRY G.;BAGCHI, DEBASIS;REEL/FRAME:013078/0979;SIGNING DATES FROM 20020520 TO 20020603

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION